Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases.

Su'an TangQinghong YuChanghai Ding

Published in: Expert opinion on investigational drugs (2022)

SYK inhibitors are promising drugs with unique advantages and acceptable tolerability and safety for the treatment of ADs. However, the difficulties in developing highly selective SYK inhibitors and the unknown effects are challenges. Long-term and real-world data are essential to determine the risk-benefit ratio and true role of SYK inhibitors in the therapy of ADs.

Keyphrases

tyrosine kinase
epidermal growth factor receptor
stem cells
randomized controlled trial
electronic health record
machine learning
clinical trial
big data
bone marrow
replacement therapy
drug induced
phase iii